Analyst Price Target is $42.67
▲ +153.37% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Pharvaris in the last 3 months. The average price target is $42.67, with a high forecast of $55.00 and a low forecast of $31.00. The average price target represents a 153.37% upside from the last price of $16.84.
Current Consensus is
Buy
The current consensus among 3 contributing investment analysts is to buy stock in Pharvaris. This rating has held steady since November 2024, when it changed from a Moderate Buy consensus rating.
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.
Read More